JP2010521534A - 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 - Google Patents

黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 Download PDF

Info

Publication number
JP2010521534A
JP2010521534A JP2010500223A JP2010500223A JP2010521534A JP 2010521534 A JP2010521534 A JP 2010521534A JP 2010500223 A JP2010500223 A JP 2010500223A JP 2010500223 A JP2010500223 A JP 2010500223A JP 2010521534 A JP2010521534 A JP 2010521534A
Authority
JP
Japan
Prior art keywords
copper
mask
copper salt
capsule material
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521534A5 (cg-RX-API-DMAC10.html
Inventor
ゲオルク・ルートヴィヒ・キス
ジャック・ヴァンデマンデ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010521534(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010521534A publication Critical patent/JP2010521534A/ja
Publication of JP2010521534A5 publication Critical patent/JP2010521534A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2010500223A 2007-03-23 2008-03-19 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 Pending JP2010521534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (en) 2007-03-23 2008-03-19 Use of a masked or coated copper salt for the treatment of macular degeneration

Publications (2)

Publication Number Publication Date
JP2010521534A true JP2010521534A (ja) 2010-06-24
JP2010521534A5 JP2010521534A5 (cg-RX-API-DMAC10.html) 2011-05-12

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500223A Pending JP2010521534A (ja) 2007-03-23 2008-03-19 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用

Country Status (26)

Country Link
US (1) US20080233182A1 (cg-RX-API-DMAC10.html)
EP (1) EP2124973B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010521534A (cg-RX-API-DMAC10.html)
KR (1) KR101688656B1 (cg-RX-API-DMAC10.html)
AR (1) AR065791A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008231847B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0809258B8 (cg-RX-API-DMAC10.html)
CA (1) CA2681514C (cg-RX-API-DMAC10.html)
CL (1) CL2008000804A1 (cg-RX-API-DMAC10.html)
CO (1) CO6230993A2 (cg-RX-API-DMAC10.html)
DK (1) DK2124973T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP099700A (cg-RX-API-DMAC10.html)
ES (1) ES2542694T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900251A (cg-RX-API-DMAC10.html)
IL (1) IL201109A (cg-RX-API-DMAC10.html)
MA (1) MA31293B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009010244A (cg-RX-API-DMAC10.html)
MY (1) MY164520A (cg-RX-API-DMAC10.html)
NZ (1) NZ579852A (cg-RX-API-DMAC10.html)
PE (1) PE20090186A1 (cg-RX-API-DMAC10.html)
PL (1) PL2124973T3 (cg-RX-API-DMAC10.html)
PT (1) PT2124973E (cg-RX-API-DMAC10.html)
RU (1) RU2009139002A (cg-RX-API-DMAC10.html)
TN (1) TN2009000387A1 (cg-RX-API-DMAC10.html)
TW (1) TW200904456A (cg-RX-API-DMAC10.html)
WO (1) WO2008116806A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533731A (ja) * 2019-05-22 2022-07-25 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト アスコルビン酸塩の形態のビタミンｃを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102421422A (zh) 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
JPH11502838A (ja) * 1995-03-29 1999-03-09 ザ、プロクター、エンド、ギャンブル、カンパニー キサンチン誘導体を含むゼラチン外殻を有するソフトゼラチンカプセル
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249821A1 (en) * 2004-05-08 2005-11-10 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2006017179A1 (en) * 2004-07-09 2006-02-16 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (cg-RX-API-DMAC10.html) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
JPH11502838A (ja) * 1995-03-29 1999-03-09 ザ、プロクター、エンド、ギャンブル、カンパニー キサンチン誘導体を含むゼラチン外殻を有するソフトゼラチンカプセル
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249821A1 (en) * 2004-05-08 2005-11-10 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2006017179A1 (en) * 2004-07-09 2006-02-16 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
WO2006055965A2 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5010007784; ＢＯＳＥ，Ｐ．Ｋ．　ｅｔ　ａｌ: ＣＡＲＢＯＨＹＤＲＡＴＥ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．３２３，　Ｎｏ．１-４, 19990112, ｐ．６３-７２, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＴＩＦＩＣ　ＰＵＢＬＩＳＨＩＮＧ　ＣＯＭＰＡＮＹ *
JPN6013016498; 岡野定輔: 新・薬剤学総論 改訂第３版, 1987, ｐ．１４３，　１４４, 南江堂 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533731A (ja) * 2019-05-22 2022-07-25 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト アスコルビン酸塩の形態のビタミンｃを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物
JP7536045B2 (ja) 2019-05-22 2024-08-19 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト アスコルビン酸塩の形態のビタミンｃを含む、ビタミンおよびミネラルのソフトゲルカプセル調製物

Also Published As

Publication number Publication date
AR065791A1 (es) 2009-07-01
US20080233182A1 (en) 2008-09-25
BRPI0809258A2 (pt) 2014-09-23
MX2009010244A (es) 2009-10-26
MA31293B1 (fr) 2010-04-01
IL201109A0 (en) 2010-05-17
DK2124973T3 (da) 2015-06-22
KR101688656B1 (ko) 2016-12-21
EP2124973A1 (en) 2009-12-02
AU2008231847A1 (en) 2008-10-02
BRPI0809258B8 (pt) 2021-05-25
GT200900251A (es) 2018-10-08
CA2681514C (en) 2016-11-08
PT2124973E (pt) 2015-09-01
NZ579852A (en) 2012-03-30
CA2681514A1 (en) 2008-10-02
MY164520A (en) 2017-12-29
PE20090186A1 (es) 2009-03-20
TN2009000387A1 (en) 2010-12-31
CL2008000804A1 (es) 2008-10-24
TW200904456A (en) 2009-02-01
IL201109A (en) 2016-10-31
PL2124973T3 (pl) 2015-10-30
AU2008231847B2 (en) 2012-12-06
EP2124973B1 (en) 2015-05-27
CO6230993A2 (es) 2010-12-20
BRPI0809258B1 (pt) 2019-10-01
RU2009139002A (ru) 2011-04-27
ES2542694T3 (es) 2015-08-10
ECSP099700A (es) 2009-11-30
WO2008116806A1 (en) 2008-10-02
KR20100015799A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
US9012501B2 (en) Type A gelatin capsule containing PUFA in free acid form
ES2606392T3 (es) Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas
AU2013314453B2 (en) A pharmaceutical composition
US20100112075A1 (en) Compositions of microparticles and granules for oral controlled release of substances for veterinary use
JP2005527207A (ja) 生理的に認容される、リン脂質を含有する、安定でかつ硬質のマトリックス
JP2010521534A5 (cg-RX-API-DMAC10.html)
JP2007504197A (ja) ホスファチジルセリン塩基の生理学的活性組成物
CA2681514C (en) Use of a masked or coated copper salt for the treatment of macular degeneration
TW201000027A (en) Organic compounds
CN101668533A (zh) 被掩蔽或包涂的铜盐在治疗黄斑变性中的用途
WO2005025544A1 (en) Enteric delivery of (-)-hydroxycitric acid
EA046793B1 (ru) Применение композиции (варианты) для профилактического или терапевтического лечения кальцификации сосудов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130924